Filing and reporting period
Important identity discrepancy: The request identifies Jade Biosciences, Inc., but the supplied filing is Aerovate Therapeutics, Inc.’s Form 10-Q for the quarter ended June 30, 2021. This summary covers the supplied Aerovate filing, not Jade Biosciences.
Aerovate is a clinical-stage biotechnology company developing AV-101, an inhaled dry-powder formulation of imatinib for pulmonary arterial hypertension (PAH). It had completed a Phase 1 study in healthy volunteers and planned to begin a Phase 2b/3 PAH trial in the second half of 2021. The company had no approved products or product revenue.
Financial performance and position
Amounts below are in millions, except per-share data. The filing reports no revenue, so revenue-based margins are not meaningful.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Research and development expense | $4.327 | $1.471 | $6.523 | $2.677 |
| General and administrative expense | $1.447 | $0.154 | $2.031 | $0.306 |
| Total operating expenses | $5.774 | $1.625 | $8.554 | $2.983 |
| Net loss | $5.775 | $2.202 | $8.556 | $3.638 |
| Net loss per share, basic and diluted | $23.80 | $9.12 | $35.29 | $15.07 |
At June 30, 2021, cash and cash equivalents were $59.150 million, total assets $62.434 million, current liabilities $4.193 million, and accumulated deficit $21.985 million. Six-month operating cash use was $7.780 million; investing cash use was $0.040 million; and financing provided $62.397 million, primarily from Series A preferred-stock sales. The company reported no long-term debt obligations.
After quarter-end, Aerovate completed its July 2 IPO, reporting approximately $127 million in net proceeds. Pro forma cash at June 30, assuming the IPO transactions had occurred then, was $186.150 million. Management said existing cash plus IPO proceeds were expected to fund planned operations into the second half of 2025. That estimate is subject to change as development costs and trial timing evolve.
Material changes versus the prior comparable period
- Q2 net loss increased $3.573 million year over year; six-month net loss increased $4.918 million.
- Q2 R&D expense rose $2.856 million, primarily from higher clinical and manufacturing costs. Six-month R&D rose $3.846 million, mainly from clinical costs, manufacturing, and personnel-related costs.
- Q2 G&A expense increased $1.293 million, principally reflecting professional services and personnel-related costs. The six-month increase was $1.725 million.
- Cash increased from $4.573 million at year-end 2020 to $59.150 million at June 30, 2021, primarily due to preferred-stock financing. The subsequent IPO further strengthened liquidity.
- Convertible promissory notes had converted to Series A preferred stock in August 2020; accordingly, the 2021 period had no related fair-value expense, unlike 2020.
Outlook, risks, and notable items
- Management expected substantial operating losses and rising expenses as AV-101 development, public-company costs, hiring, and potential commercialization preparations continued.
- The planned Phase 2b/3 study was to begin in the second half of 2021. The filing described a Phase 2b target enrollment of 200 patients and anticipated topline Phase 2b results in mid-2023.
- Key risks include clinical-trial failure or delay, patient recruitment challenges, uncertain safety and efficacy in PAH patients, regulatory and drug-device approval requirements, reliance on third-party manufacturers and a sole-source inhaler supplier, competition, and dependence on additional capital if costs exceed plans.
- COVID-19 could affect enrollment, trial sites, suppliers, manufacturing, and timelines. The filing said a COVID-related site closure had briefly delayed the Phase 1 trial.
- The filing notes the auditor’s prior-year going-concern explanatory paragraph. After considering the IPO proceeds and existing cash, management concluded funds should cover obligations for at least 12 months from issuance of the interim financial statements.
- The company reported no material litigation, no off-balance-sheet arrangements, and no long-term contractual obligations as of June 30. An August 2021 office lease was expected to commence in September, with base rent of about $0.2 million annually for 39 months.
- The filing contains inconsistent IPO share figures: the financial-statement notes report 9,984,463 shares issued, while Item 2 reports 8,682,142 shares issued, including an over-allotment of 1,302,231. The proceeds and post-IPO share totals should be checked against the IPO prospectus and related filings.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Aerovate Therapeutics, Inc., not Jade Biosciences, Inc.
- Reconcile the IPO share-count discrepancy and confirm net proceeds, conversion shares, and post-IPO shares outstanding.
- Track whether the Phase 2b/3 trial began as planned, enrollment progress, safety findings, and the timing and interpretation of topline data.
- Assess cash burn and trial/manufacturing spending against management’s projected runway into the second half of 2025.
- Review regulatory feedback, intellectual-property developments, and the availability of the third-party drug and inhaler supply chain.